IIAM and Ambys Medicines have entered into an exciting collaboration for therapeutic application in treating patients with acute and chronic liver failure. Ambys is proud to partner with IIAM and its expansive OPO network in obtaining non-transplantable livers from donors where viable cells can be isolated and expanded through Ambys’ proprietary technology. Ambys Medicines is dedicatedContinue reading
It is with great excitement that we announce Shannon Edwards as the IIAM Regional Director – East Coast! Shannon brings a wealth of experience to IIAM. Many of you know Shannon from her nearly 17 years at UNOS, most recently as Manager, Policy and Community Relations and preceded by roles in Regional Administration (RA); includingContinue reading
Lungs obtained through IIAM for the NIH-funded LungMAP project have contributed to a new study helping GE scientists learn more about the effects of COVID-19 to enable the development of better treatments for patients suffering from this virus. Click here for full press release
Everyone who reads this story is engaged in a noble cause; but it’s also a business. With more demand than ever for research organs, specifically livers, the decisions made by OPOs and the partnerships they forge can impact outcomes and future expectations.
Carolina Donor Services (CDS) is ideally positioned to provide non-transplantable organs to one of the most prominent research hubs in the U.S. Early in 2019, IIAM partnered with leadership at the OPO to maximize the placement of more organs for medical research.
Based on suggestions from our partners, IIAM has continued to make system upgrades that improve our entire referral process — the latest of which enables any referring OPO to update referrals electronically.